Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a thera…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.01 | $-0.01 | $0.01 | $-1.00 |
| Estimado | $-0.01 | $-0.01 | $-0.01 | $-0.58 |
| Sorpresa | +0.0% | +0.0% | +200.0% | -72.4% |
| Métrica | EVAX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -122.7% | -34.4% | -88.3% |
| Net Margin | -102.4% | -32.5% | -69.9% |
| FCF Margin | -88.2% | -12.6% | -75.6% |
| ROE | -45.2% | -39.2% | -6.1% |
| ROA | -27.1% | -30.9% | +3.8% |
| Current Ratio | 5.85 | 2.73 | +3.12 |
| Debt / Equity | 0.31 | 0.28 | +0.03 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -27.1% | — |
| ✗Flujo de caja operativo positivo | −$7M | −$13M |
| ✓Rentabilidad sobre activos al alza | -27.1% | -84.6% |
| ✓Caja operativa/activos supera al ROA | -23.3% | ROA -27.1% |
| ✓Menos deuda a largo plazo | 18.8% | 64.1% |
| ✓Mejor liquidez (ratio corriente) | 5.85 | 2.01 |
| ✗Sin aumentar el nº de acciones | 320M | 54M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.26 | 0.27 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -88.2% |
| ✗ROCE > 10 % | -38.2% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 132.7% |
Evaxion A/S cotiza a 2.83 USD y tiene una capitalización bursátil de $26M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud